STOCK TITAN

Penumbra, Inc. to Participate in CEO Discussion with Bank of America

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ALAMEDA, Calif., Dec. 4, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its chief executive officer is scheduled to participate in a discussion with Bank of America on Tuesday, December 8, 2020.

Event: CEO Discussion with Bank of America
Date: Tuesday, December 8, 2020
Time: 8:30am ET / 5:30am PT

An audio webcast of the discussion will be available by visiting the investors' section of the company's website at www.penumbrainc.com.  The audio webcast will be available on the company's website for at least two weeks following the event.

About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets. The Penumbra logo is a trademark of Penumbra, Inc. For more information, visit www.penumbrainc.com.

Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/penumbra-inc-to-participate-in-ceo-discussion-with-bank-of-america-301186771.html

SOURCE Penumbra, Inc.

Penumbra Inc

NYSE:PEN

PEN Rankings

PEN Latest News

PEN Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Alameda

About PEN

penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.